Biotech Values

[corky]

GTC Biotherapeutics-GTCB and PharmAthene-PIP extend agreementGTC Biotherapeutics, Inc. has entered into an extended agreement with PharmAthene, Inc. under which GTC will provide continuing process development and clinical supply manufacturing services for PharmAthene's Protexia(R) program. The manufacturing work is planned to conclude in the third quarter of 2008. Protexia(R) is a recombinant form of human butyrylcholinesterase produced in the milk of transgenic goats, which is being developed by PharmAthene as a pre- and post-exposure therapy for victims of a chemical nerve agent attack. :theflyonthewall.com